# US 2024/0391870 A1 · Ionizable cationic lipids for rna delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391870 A1
- Document ID: US20240391870A1
- Status: Published application
- Kind: A1
- Application number: 18/660,219
- Filed: 2024-05-09
- Published: 2024-11-28
- Earliest claimed: 2023-05-10
- Assignees: Arcturus Therapeutics, Inc.
- Applicants: Arcturus Therapeutics, Inc.
- Inventors: Kumar Rajappan; Steven Tanis
- Web page: https://patentgrep.com/patent/US20240391870A1

## CPC

- C07C 333/04: having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- C07C 229/12: to carbon atoms of acyclic carbon skeletons
- C07C 229/16: to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
- C07C 237/12: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups (peptides C07K)
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 275/16: being further substituted by carboxyl groups
- C07C 327/06: to hydrogen atoms or to carbon atoms of an acyclic saturated carbon skeleton
- C07C 327/32: having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07D 209/24: with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
- C07D 333/60: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C07C 2601/14: The ring being saturated
- C07C 2602/24: the ring system containing nine carbon atoms, e.g. perhydroindane
- C12N 2310/14: interfering nucleic acids [NA]
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:

## Claims

### Claim 1

A compound of Formula I, or a pharmaceutically acceptable salt thereof:
wherein:
R1 and R2 are each independently H or C1-6 alkyl; or
R1 and R2 are joined to form a saturated heterocyclic ring, wherein:
R1 is a linear C1-4 alkylene; and
R2 is —(CH2)m(X)n—, wherein
X is O, S, or NR9, wherein R9 is H or C1-6 alkyl;
m is 1, 2, 3 or 4, and
n is 0 or 1;
L1 is a linear C1-6 alkylene optionally substituted with one to three methyl groups;
Y is selected from the group consisting of:
wherein:
each asterisk (*) indicates the atom attached to L2 and L3; and
R10 is H or C1-6 alkyl;
L2 and L3 are each independently a linear C1-8 alkylene;
L4, L5, L6, L7, L8 and L9 are each independently absent or —CH2—, provided that:
at least two of L4, L6 and L8 are —CH2—; and
at least two of L5, L7 and L9 are —CH2—;
R3 and R4 are each independently H, methyl or ethyl; and
R5, R6, R7 and R8 are each independently selected from the group consisting of:
linear C1-20 alkyl, wherein each said linear C1-20 alkyl is optionally substituted with one or more substituents selected from the group consisting of:
C6-10 aryl, wherein each said C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryl that is optionally substituted with one or more C1-6 alkyl;
6-10 membered heteroaryl, wherein each said 6-10 membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl;
C6-10 aryl, wherein each said C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryl that is optionally substituted with one or more C1-6 alkyl; and
6-10 membered heteroaryl, wherein each said 6-10 membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein Y is selected from the group consisting of:

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 5)

The compound of claim 5, wherein:
at least one of R1 and R2 is H; and
L1 is —CH2— or —CH2CH2—.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R1 and R2 are each independently C1-6 alkyl.

### Claim at position 7

-14. (canceled)

### Claim 15 (depends on 1)

The compound of claim 1, wherein R5, R6, R7 and R8 are each independently linear C1-8 alkyl, wherein each said linear C1-8 alkyl is optionally substituted with one or more substituents selected from:
C6-10 aryl, wherein each said C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryl that is optionally substituted with one or more C1-6 alkyl; and
6-10 membered heteroaryl, wherein each said 6-10 membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R5, R6, R7 and R8 are each independently C6-10 aryl, wherein each said C6-10 aryl is a monocyclic or bicyclic aromatic hydrocarbon optionally substituted with one or more C6-10 aryl that is optionally substituted with one or more C1-6 alkyl.

### Claim 17 (depends on 1)

The compound of m claim 1, wherein R5, R6, R7 and R8 are each independently a 6-10 membered heteroaryl, wherein each said 6-10 membered heteroaryl is a monocyclic or bicyclic aromatic system optionally substituted with one or more C1-6 alkyl.

### Claim at position 11

-19. (canceled)

### Claim 20 (depends on 1)

The compound of claim 1, wherein L1 is linear unsubstituted alkylene.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The compound of claim 1, wherein L2 and L3 are each independently linear C1-5 alkylene.

### Claim at position 15

-26. (canceled)

### Claim 27 (depends on 1)

The compound of claim 1, wherein L4, L5, L6, L7, L8 and L9 are each —CH2—.

### Claim 28 (depends on 1)

The compound of claim 1, wherein L6, L7, L8 and L9 are each —CH2—; and L4 and L5 are absent.

### Claim 29 (depends on 1)

The compound of claim 1, wherein L4, L5, L8 and L9 are each —CH2—; and L6 and L7 are absent.

### Claim 30 (depends on 1)

The compound of claim 1, wherein L4, L5, L6 and L7 are each —CH2—; and L8 and L9 are absent.

### Claim at position 20

-33. (canceled)

### Claim 34 (depends on 1)

The compound of claim 1, selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 35

A compound selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 36 (depends on 1)

A lipid composition comprising a nucleic acid and a compound of claim 1.

### Claim 37 (depends on 36)

The lipid composition of claim 36, wherein the nucleic acid is selected from an siRNA, an mRNA, a self-replicating RNA, a DNA plasmid, and an antisense oligonucleotide.

### Claim 38 (depends on 36)

The lipid composition of claim 36, wherein the nucleic acid is a mRNA or a self-replicating RNA comprising a coding region that encodes a therapeutic protein of interest.

### Claim 39 (depends on 38)

The lipid composition of claim 38, wherein the therapeutic protein of interest is an enzyme, and antibody, an antigen, a receptor, or a transporter.

### Claim 40 (depends on 38)

The lipid composition of claim 38, wherein the therapeutic protein of interest is a gene-editing enzyme.

### Claim 41 (depends on 40)

The lipid composition of claim 40, wherein the gene-editing enzyme is selected from a TALEN, a CRISPR, a meganuclease, or a zinc finger nuclease.

### Claim 42 (depends on 36)

The lipid composition of claim 36, wherein the lipid composition comprises liposomes, lipoplexes, or lipid nanoparticles.

### Claim at position 30

-51. (canceled)

### Claim 52 (depends on 36)

The lipid composition of claim 36, wherein the lipid nanoparticle composition further comprises a helper lipid selected from: dioleoylphosphatidyl ethanolamine (DOPE), dimyristoylphosphatidyl choline (DMPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidyl glycerol (DMPG), dipalmitoyl phosphatidylcholine (DPPC), and phosphatidylcholine (PC).

### Claim 53

(canceled)

### Claim 54 (depends on 36)

The lipid composition of claim 36, further comprising cholesterol.

### Claim 55 (depends on 36)

The lipid composition of claim 36, further comprising a polyethylene glycol(PEG)-lipid conjugate.

### Claim at position 35

-57. (canceled)

### Claim 58 (depends on 1, 36)

The lipid composition of claim 36, wherein the lipid composition comprises a lipid nanoparticle of comprising about 45 mol % to 65 mol % of the compound of claim 1, about 2 mol % to about 15 mol % of a helper lipid, about 20 mol % to about 42 mol % of cholesterol, and about 0.5 mol % to about 3 mol % of a PEG-lipid conjugate.

### Claim at position 37

-60. (canceled)

### Claim 61 (depends on 36)

The lipid composition of claim 36, wherein the lipid nanoparticle has a total lipid:nucleic acid weight ratio of about 50:1 to about 10:1.

### Claim at position 39

-65. (canceled)

### Claim 66 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, and a pharmaceutically acceptable excipient.

### Claim 67 (depends on 66)

The pharmaceutical composition of claim 66, wherein the pharmaceutical composition is a lyophilized composition.

### Claim at position 42

-70. (canceled)

### Claim 71 (depends on 66)

The pharmaceutical composition of claim 66, wherein the pharmaceutical composition further comprises one or more cryoprotectants.

### Claim 72 (depends on 71)

The pharmaceutical composition of claim 71, wherein the one or more cryoprotectants are selected from sucrose, glycerol, or a combination of sucrose and glycerol.

### Claim 73

(canceled)

### Claim 74 (depends on 66)

A method of treating a disease in a subject in need thereof, comprising administering a therapeutically effective amount to the subject, the pharmaceutical composition of claim 66.

### Claim 75 (depends on 74)

The method of claim 74, wherein the pharmaceutical composition is administered intravenously or intramuscularly.

### Claim 76 (depends on 36)

A method of expressing a protein or polypeptide in a target cell, comprising contacting the target cell with a lipid composition of claim 36.

### Claim 77 (depends on 76)

The method of claim 76, wherein the protein or polypeptide is an antigen, and expression of the antigen elicits an in vivo immunogenic response.

### Claim 78 (depends on 36)

A method of delivering a nucleic acid to a subject in needed thereof, comprising encapsulating a therapeutically effective amount of the nucleic acid in the lipid composition of claim 36, and administering the lipid composition to the subject.
